Evaluation of chemo-photodynamic therapy of multi-drug (metformin-methylene blue) conjugated to ferrofluidic nanocarrier on triple-negative breast cancer cells in hyperglycemic conditions
Nanomedicine Journal · 2025-10 · 12 (4) · 673-689
DOI: 10.22038/nmj.2025.82375.2055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanomedicine Journal, 2025-10. Verfasst von Samaneh Chalaki und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Objective(s): Previous studies have established a link between hyperglycemia (high blood sugar) and hyperinsulinemia (elevated insulin levels) in diabetes, and the subsequent promotion of cancer cell growth. Among various cancers, triple-negative breast cancer (TNBC) is one of the most aggressive types, which can exhibit heightened malignancy in the presence of diabetes. The objective of this study is to introduce a novel approach to combined chemo-photodynamic therapy (Ch-PDT) for TNBC, utilizing metformin (MET) and methylene blue (MB) conjugated to a ferrofluidic nanocarrier, targeting MDA-MB-231 breast cancer cells under conditions that simulate high blood sugar.Material and methods: To this end, Fe₃O₄f nanoparticles were synthesized via the hydrothermal method and subsequently modified with polyethylene glycol and 3-aminopropyltriethoxysilane (APTES) to enhance drug loading efficiency. The physicochemical properties of the nanoparticles were characterized using FT-IR, XRD, FE-SEM, TEM, EDX, ¹H-NMR, VSM, and UV-VIS spectroscopy. For the Ch-PDT application, the cells were incubated with the different formulations and subjected to various irradiation conditions. Cell viability was then assessed for all treatment groups using the MTT assay.
Results
Increased exposure in the MB-containing group resulted in reduced cell survival, likely due to the photosensitizing properties of methylene blue. However, in the Fe₃O₄f-PEG-MET-MB group, cell death increased significantly as the irradiation time was extended. This synergistic effect is attributed to the enhanced efficacy of combined chemo-photodynamic therapy (Ch-PDT), which optimizes the therapeutic potential of metformin (P < 0.01).
Conclusion
Based on the results, Ch-PDT can be an effective method in increasing the efficiency of metformin in inhibiting metastatic breast cancer tumor cells in hyperglycemic conditions.
Schlagwörter
Zitieren
APA
Chalaki, S., Gholizadeh, M., Akhlaghinia, B., Imanparast, A., & Sazgarnia, A. (2025). Evaluation of chemo-photodynamic therapy of multi-drug (metformin-methylene blue) conjugated to ferrofluidic nanocarrier on triple-negative breast cancer cells in hyperglycemic conditions. Nanomedicine Journal, 12(4), 673-689. https://doi.org/10.22038/nmj.2025.82375.2055
Vancouver
Chalaki S, Gholizadeh M, Akhlaghinia B, Imanparast A, Sazgarnia A. Evaluation of chemo-photodynamic therapy of multi-drug (metformin-methylene blue) conjugated to ferrofluidic nanocarrier on triple-negative breast cancer cells in hyperglycemic conditions. Nanomedicine Journal. 2025;12(4):673-689. doi:10.22038/nmj.2025.82375.2055
BibTeX
@article{Chalaki2025,
author = {Chalaki, Samaneh and Gholizadeh, Mostafa and Akhlaghinia, Batool and Imanparast, Armin and Sazgarnia, Ameneh},
title = {Evaluation of chemo-photodynamic therapy of multi-drug (metformin-methylene blue) conjugated to ferrofluidic nanocarrier on triple-negative breast cancer cells in hyperglycemic conditions},
journal = {Nanomedicine Journal},
year = {2025},
volume = {12},
number = {4},
pages = {673--689},
doi = {10.22038/nmj.2025.82375.2055}
}
EUVIMED